Vicore is an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life-changing treatments in diseases where the AT2 (angiotensin II type 2) receptor has a central role in stopping and reversing disease pathology.
A strong history of collaboration with the scientific community has led to a wealth of preclinical data and ongoing clinical research in multiple indications to prove the AT2 receptor biology. Embedded in the Vicore approach is the determination to find holistic solutions for patients and their families. Almee™ demonstrates the potential of a truly patient centric approach.
For more information, visit www.vicorepharma.com
